Vir Biotechnology, Inc. (VIR) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Vir Biotechnology’s revenue went from $3M in fiscal 2017 to $69M in fiscal 2025, growth of about 49.8% a year.
Net income in fiscal 2025 was -$438M, a net margin of -638.9%; the best year in this period was 2021 with $529M.
Over the twelve months to September 30, 2026, revenue was $303M and net income -$185M.
Free cash flow was -$397M in fiscal 2025 and positive in 1 of the 9 years shown.
The diluted share count rose 6336% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $303M | $69M | $74M | $86M | $1.6B | $1.1B | $76M | $8M | $11M | $3M |
| Gross profit | — | $69M | $73M | $83M | $1.5B | $1.0B | $76M | $8M | — | — |
| Operating income | -$211M | -$479M | -$587M | -$684M | $833M | $421M | -$297M | -$178M | -$119M | -$81M |
| Net income | -$185M | -$438M | -$522M | -$615M | $516M | $529M | -$299M | -$175M | -$116M | -$70M |
| EPS (diluted) | $-1.18 | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 | $-2.51 | $-5.76 | $-15.12 | $-32.45 |
| R&D | $413M | $456M | $506M | $580M | $475M | $448M | $302M | $148M | $100M | $63M |
| Revenue growth | — | −7.6% | −13.9% | −94.7% | +47.5% | +1334.4% | +843.9% | −24.2% | +293.9% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$141M | -$392M | -$446M | -$779M | $1.7B | -$48M | -$191M | -$130M | -$94M | -$66M |
| Capital spending | -$804000 | -$5M | -$7M | -$22M | -$68M | -$22M | -$7M | -$9M | -$8M | -$3M |
| Free cash flow | -$142M | -$397M | -$454M | -$800M | $1.6B | -$69M | -$197M | -$139M | -$102M | -$69M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $46M | $49M | $78M | $111M | $102M | $84M | $28M | $9M | $5M | $5M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $461M | $901M | $1.5B | $2.4B | $565M | $737M | $383M | $98M | $188M |
| Debt | — | $98M | $98M | $125M | $128M | $137M | $70M | $0 | $0 | — |
| Equity | — | $765M | $1.2B | $1.6B | $2.1B | $1.4B | $717M | $424M | -$179M | -$69M |
| Total assets | — | $1.0B | $1.4B | $1.9B | $2.8B | $2.0B | $919M | $512M | $192M | — |
| Shares (diluted) | 169M | 139M | 136M | 134M | 135M | 133M | 119M | 30M | 8M | 2M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 100.0% | 98.9% | 96.8% | 90.9% | 94.0% | 100.0% | 100.0% | — | — |
| Operating margin | -69.8% | -699.2% | -791.3% | -794.0% | 51.6% | 38.4% | -388.9% | -2199.7% | -1112.6% | -3009.5% |
| Net margin | -61.0% | -638.9% | -703.4% | -713.7% | 31.9% | 48.2% | -391.1% | -2159.0% | -1086.3% | -2579.5% |
| FCF margin | -46.8% | -578.5% | -611.4% | -928.7% | 98.7% | -6.3% | -258.6% | -1712.7% | -958.8% | -2552.6% |
| ROIC | — | -43.9% | -46.9% | -39.1% | 25.8% | 25.8% | -29.8% | -33.2% | — | — |
| ROE | — | -57.2% | -45.4% | -38.7% | 24.8% | 36.9% | -41.7% | -41.2% | 64.7% | 101.4% |
Frequently asked questions
What is Vir Biotechnology’s annual revenue?
$69M in fiscal 2025 and $303M over the twelve months to September 30, 2026.
How much profit does Vir Biotechnology make?
Net income was -$438M in fiscal 2025 (net margin -638.9%).
Is Vir Biotechnology’s revenue growing?
No: revenue fell 7.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.